Falling prices. The initial Human Genome Project took 10 years and cost more than $3 billion US Dollars. The $1000 genome catch phrase was first used in 2001 and indicated that prices would need to fall significantly to allow for genome sequencing to be used for routine diagnostics. Currently, in 2014, the $1000 genome seems on the horizon. However, will we ever have a $1000 epilepsy genome? Continue reading
Monthly Archives: June 2014
Magnesium, epilepsy, and CNNM2 mutations
Electrolytes. Sodium, calcium, and magnesium – I usually tell my students that imbalances in these serum electrolytes may result in seizures, when levels fall under a critical threshold. Amongst these imbalances, hypomagnesemia, a reduction of the serum magnesium level below 0.7 mmol/L, is a very rare cause of seizures, particularly in a pediatric population. However, there are genetic conditions that result in reduced magnesium levels and lead to neurological complications. In a recent paper in PLOS Genetics, the phenotype of CNNM2 mutation carriers is investigated – and magnesium is only the beginning of the story. Continue reading
Publications of the week – 16p11.2 duplications, autism CNVs, and SETD1A
This week. This week’s publications in epilepsy genetics might be interesting for you, as they describe the first genetic risk factor for typical rolandic epilepsies, novel CNV studies in autism, and an unexpected de novo mutation in schizophrenia. Continue reading
The top three publications in epilepsy genetics 25 years ago
Looking back. In this week’s ILAE Genetics Commission post, we would like to look 25 years back and examine the most important publication in the field in 1989, the year the Berlin wall fell. What concepts did we have back then and how did our understanding of epilepsy and genes change? Here are the top three publications of 1989. Continue reading
Switching inhibition on – SLC12A5/KCC2 variants in human epilepsy
Inhibition. We usually like to think of GABA as an inhibitory neurotransmitter, which counteracts the excitatory and potentially epileptogenic effects of glutamate. However, this is not always true during brain development. Initially, GABA is a powerful excitatory neurotransmitter. The excitatory effect of GABA has been shown to be important for brain development and the formation of dendritic spines – and the switch from excitation to inhibition is due to a single ion channel: KCC2, encoded by SLC12A5. Two recent publications in EMBO Reports now implicate genetic variation in SLC12A5 in human epilepsy. Continue reading
Publications of the week – GABRB3, SLC2A1, and SCN1A
No novel genes. This was actually a slow week with respect to publications in epilepsy genetics. No new gene was published, so we’ll focus on three publications that tell us bit more about three genes that we already know. This week’s publications cover new reports on GABRB3, SLC2A1, and SCN1A in brain malformations. Continue reading
Precision medicine in genetic epilepsies – three criteria to consider
Three criteria. You hear the phrase precision medicine quite frequently these days and might wonder what this is all about. In a nutshell, in the context of genetic epilepsies, the basic idea behind precision medicine is to use genetic patient information for treatment decisions. The broader vision behind this aims at improving the lives of individuals with epilepsy by making smarter and faster treatment decisions, which lead to better treatment response and fewer side effects. But how should we assess information on reports of precision medicine in the literature? Here are the three important criteria to assess. Continue reading
How genome sequencing in intellectual disability breaks the 50% boundary
Exome failures. Trio exome sequencing has the huge potential to discover the genetic basis of neurodevelopmental disorders. However, the results are negative for the majority of patients. In a recent study published in Nature, genome sequencing was applied to exome-negative patients with intellectual disability, identifying mutations in coding regions that were previously missed. But are the authors correct in stating that they can explain more than 60% of cases in an unselected cohort? Continue reading
Publications of the week – SCN8A, CNTNAP4, EML1, and SCN1A
Catching up. This week’s review of recent publications might be relevant for you because it adds new pertinent details to known epilepsy genes and discusses novel gene findings that might be applicable in clinical practice. This post covers publications on SCN8A in epileptic encephalopathy, CNTNAP4 and interneurons, EML1 in brain malformations, and the meaning of SCN1A variants in small epilepsy families. Continue reading
We want you to be an Epilepsiome builder
YESTI. On behalf of the ILAE Genetics Commission, we are looking for young clinician scientists who would like to help us build the Epilepsiome – a comprehensive, up-to-date database on epilepsy and genes. We are looking for YESTI’s – “young experts with sufficient time and interest”. Read more about what we would expect from you. Continue reading